Tercica, Fujisawa IP deal for IGF-1

Fujisawa granted TRCA a non-exclusive license to IP covering the use of recombinant human Insulin-Like Growth Factor-1 ( rhIGF-1) to treat certain forms of extreme insulin resistance. TRCA's rights ex...